This review focuses on the role of long noncoding RNAs (lncRNAs) in glioblastoma multiforme (GBM), an aggressive form of brain cancer with a poor prognosis. LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into proteins but play crucial roles in cellular processes and functions. They are highly tissue-specific and have been implicated in various diseases, including cancer. The expression of lncRNAs in the nervous system varies across different cell types and is involved in mechanisms affecting neuron and glial development and function. Changes in lncRNA molecules have been linked to the etiopathogenesis of brain neoplasia, including GBM. GBM is characterized by highly invasive malignant cells that spread throughout the neural tissue, making complete resection challenging and leading to frequent post-surgery recurrences. Early diagnosis and effective treatment are crucial for improving patient outcomes. The profiling of lncRNAs in biological fluids, such as blood, offers a promising approach for detecting neoplastic changes at early stages and facilitating more effective therapeutic interventions. The review systematically examines the deregulation of lncRNAs associated with GBM, highlighting their diagnostic and prognostic relevance. It discusses the molecular mechanisms by which lncRNAs interact with biomolecules and influence cellular processes. Key lncRNAs associated with GBM, such as AC016405.3, ANRIL, CASC2, CRNDE, DGC R5, GAS5, LINC00467, LINC00641, and MIR210HG, are detailed, including their expression patterns, functional roles, and potential as biomarkers. The review also emphasizes the importance of standardized nomenclature and the need for further research to identify specific lncRNA signatures for better diagnostic and prognostic applications. The detection of changes in a set of lncRNAs, rather than a single molecule, can provide higher specificity and sensitivity in diagnosing and monitoring GBM. The potential of lncRNAs as biomarkers is further supported by their stability in biological fluids and their ability to be detected using advanced analytical methods. In conclusion, the study of lncRNAs in GBM offers valuable insights into disease mechanisms and potential therapeutic targets. The identification and characterization of specific lncRNA signatures can enhance the accuracy of diagnosis and prognosis, ultimately improving patient outcomes.This review focuses on the role of long noncoding RNAs (lncRNAs) in glioblastoma multiforme (GBM), an aggressive form of brain cancer with a poor prognosis. LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into proteins but play crucial roles in cellular processes and functions. They are highly tissue-specific and have been implicated in various diseases, including cancer. The expression of lncRNAs in the nervous system varies across different cell types and is involved in mechanisms affecting neuron and glial development and function. Changes in lncRNA molecules have been linked to the etiopathogenesis of brain neoplasia, including GBM. GBM is characterized by highly invasive malignant cells that spread throughout the neural tissue, making complete resection challenging and leading to frequent post-surgery recurrences. Early diagnosis and effective treatment are crucial for improving patient outcomes. The profiling of lncRNAs in biological fluids, such as blood, offers a promising approach for detecting neoplastic changes at early stages and facilitating more effective therapeutic interventions. The review systematically examines the deregulation of lncRNAs associated with GBM, highlighting their diagnostic and prognostic relevance. It discusses the molecular mechanisms by which lncRNAs interact with biomolecules and influence cellular processes. Key lncRNAs associated with GBM, such as AC016405.3, ANRIL, CASC2, CRNDE, DGC R5, GAS5, LINC00467, LINC00641, and MIR210HG, are detailed, including their expression patterns, functional roles, and potential as biomarkers. The review also emphasizes the importance of standardized nomenclature and the need for further research to identify specific lncRNA signatures for better diagnostic and prognostic applications. The detection of changes in a set of lncRNAs, rather than a single molecule, can provide higher specificity and sensitivity in diagnosing and monitoring GBM. The potential of lncRNAs as biomarkers is further supported by their stability in biological fluids and their ability to be detected using advanced analytical methods. In conclusion, the study of lncRNAs in GBM offers valuable insights into disease mechanisms and potential therapeutic targets. The identification and characterization of specific lncRNA signatures can enhance the accuracy of diagnosis and prognosis, ultimately improving patient outcomes.